Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Green spaces, especially forest, reduce COVID-19 incidence, study says

An intriguing new study reveals that the closer you are to green spaces, especially forests, the less likely you are to be infected with SARS-CoV-2.

10 Aug 2021

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

A new study reports a more rapid method of viral inactivation in an effort to increase the appeal of inactivated viral vaccines against the COVID-19 pandemic.

10 Aug 2021

IMBA researchers may have found the "Achilles' heel" of SARS-CoV-2 virus

Researchers identify two sugar-binding proteins that impede the viral entry of circulating SARS-CoV-2 variants.

10 Aug 2021

SARS-CoV-2 variants and their ability to infect mice

A new study published on the bioRxiv* preprint server has conducted in silico studies along with in vitro, in vivo, and in situ observations and indicated the mouse adaptation of SARS-CoV-2.

10 Aug 2021

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.

9 Aug 2021

A multi-scale cryo-correlative platform to image SARS-CoV-2 in Vero cells

A new study describes the cytopathic episodes triggered by SARS-CoV-2 with virus replication processes in frozen-hydrated cells.

9 Aug 2021

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

The spike protein comprises of two subunits: S1 subunit having the receptor-binding domain (RBD) that helps it to bind to the angiotensin-converting enzyme 2 (ACE2), which is present on the cell surface of the host, and the S2 subunit that helps in the fusion of the cellular membrane and the viral membrane.

9 Aug 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Researchers in the United States have developed a new model for testing mutations in the four structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Aug 2021

Affinity maturation of SARS-CoV-2 antibodies make them more powerful and resistant to escape mutations

A new study in the journal Immunity shows in fascinating detail how antibodies elicited by this virus show affinity maturation, a process occurring by somatic hypermutation (SHM) in the lymphoid germinal centers, to become more specific in their recognition of antigens.

6 Aug 2021

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive and viable option against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is published in the journal Advanced Therapeutics.

5 Aug 2021

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

A new study discusses the development of an improved protocol based on cell lines that can consistently express S proteins.

5 Aug 2021

COVID vaccines generate antibodies in saliva

Researchers in the United States and Canada have conducted a study showing that the vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) generate local antibody responses in the salivary gland that are independent of the systemic immune response.

5 Aug 2021

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States and Canada have described the structural basis and mode of action for two monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2021

Monoclonal antibody could inform development of pan-coronavirus vaccines

Researchers in the United States have demonstrated the potential of a monoclonal antibody to inform the design of pan-coronavirus vaccines that could prevent the outbreak of future pandemics such as coronavirus disease 2019 (COVID-19).

4 Aug 2021

Inhibition of SARS-CoV-2 replication in vitro by Losartan

A new study explores the use of Losartan to provide protection against COVID-19 pathogenesis.

3 Aug 2021

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

A recent study from the University of Rochester reveals how the biodistribution kinetics and the affinity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for many different organs in the human body can be affected by antibodies targeting viral spike glycoprotein. The paper is currently available on the bioRxiv* preprint server while it undergoes peer review.

3 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Angiotensin News and Research

Further Reading

Green spaces, especially forest, reduce COVID-19 incidence, study says

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

IMBA researchers may have found the "Achilles' heel" of SARS-CoV-2 virus

SARS-CoV-2 variants and their ability to infect mice

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

A multi-scale cryo-correlative platform to image SARS-CoV-2 in Vero cells

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

New insight into impact of SARS-CoV-2 mutations on receptor binding

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Affinity maturation of SARS-CoV-2 antibodies make them more powerful and resistant to escape mutations

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

COVID vaccines generate antibodies in saliva

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Monoclonal antibody could inform development of pan-coronavirus vaccines

Inhibition of SARS-CoV-2 replication in vitro by Losartan

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

“Sybodies” protect against SARS-CoV-2 in hamster model

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News